Blog

For decades, the fight against cancer has been a relentless battle of incremental gains. While immunotherapies like CAR-T cell therapy have offered revolutionary hope, their personalized nature, high cost, and severe side effects have limited their reach. But what if there was a readily available, “off-the-shelf” solution that could overcome these hurdles? Recent breakthroughs in cellular immunotherapy are pointing to a powerful new contender: Chimeric Antigen Receptor (CAR)-Natural Killer (NK) cells. These engineered immune cells are demonstrating the ability to effectively target and destroy cancer cells with a safety profile that could make cutting-edge treatments accessible to more pati …